close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Santhera Pharmaceuticals Holding AG

< Previous 1 2 3 Next >
News headline image
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Publishes Timeline of the Reverse Share Split
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Publishes Agenda for its Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Publishes Annual Report 2022
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Vamorolone NDA mid-cycle review meeting by FDA completed
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera enters into CHF 5 million share exchange agreement
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Calls Extraordinary General Meeting to Seek Approval for Further Financings
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.